Lilly lung cancer med up for FDA panel review; AZ, Ironwood eye China filing for Linzess;

> Eli Lilly's ($LLY) experimental lung cancer drug nectumumab is set for an FDA advisory panel meeting Thursday, with agency reviewers asking the expert members to address the drug's blood-clotting risks. Report

> AstraZeneca ($AZN) and partner Ironwood ($IRWD) said their constipation drug Linzess met its goals in a new trial aimed at a regulatory filing in China. Report

> Sanofi ($SNY) is taking two new malaria combo treatments into Phase IIb trials, with one of the artemisinin-free meds--OZ439/Piperquine--already in study and the other--OZ439/Ferroquine--set to start this summer. Release | Report

> Eisai rolled out its epilepsy drug Fycompa for a new indication in the U.K., for another type of seizures. Report

> Hi-Tech Pharmaceuticals snapped up another company in the nutrition and weight loss field, Innovative Laboratories, to expand in diet remedies in the U.S. Release

> Novo Nordisk ($NVO) picked up a set of awards for its investor relations work, including a best-in-class nod for large-cap companies in Europe. Report

And Finally... Oregon has dramatically expanded women's access to birth control. Report

Suggested Articles

Merck’s Keytruda is battling Bristol Myers' Opdivo in adjuvant melanoma, and it just racked up trial results that will help it even the playing field.

While the failure might be a missed chance at revenue, it shouldn’t hurt Ibrance’s ability to rack up sales in the metastatic setting, one exec says.

One combination of Tecentriq and chemo, when used before surgery, delivered significant benefits